Animal models of inflammatory bowel disease: Insights into the immunopathogenesis of Crohn's disease and ulcerative colitis

Current Opinion in Gastroenterology

Volumn 14, Issue 6, 1998, Pages 476-482

  Fuss, Ivan J ^a   Strober, Warren ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CROHN DISEASE; HOMEOSTASIS; IMMUNOPATHOGENESIS; INTESTINE MUCOSA; MOUSE; NONHUMAN; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 0032452759     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199811000-00010     Document Type: Review

References (48)

1. Powrie F, Mason D: OX-22 high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 1991, 172:1701-1708.
2. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
3. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
4. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S: Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993, 75:275-282.
5. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
6. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W: Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997, 158:566-573.
7. Ludviksson BR, Ehrhardt RO, Strober W: TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997, 159:3622-3628. This was the first study to demonstrate that IL-2 is necessary for the induction of TGF-β as a counter-regulatory cytokine of Th1 inflammatory responses in vivo.
8. Hornquist CE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, Birnbaumer L, Harriman GR: G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 1997, 158:1068-1077. Well-controlled studies, in a model other than a gene-targeted deletion, that display intestinal inflammation secondary to a dysregulated IL-12-driven Th1 IFN-γ response.
9. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Bradley A, Birnbaumer L: Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J Clin Immunol 1995, 15(suppl):101S-105S.
10. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996, 98:1010-1020.
11. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
12. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR: Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996, 157:2174-2185.
13. Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F: Inflammatory bowel disease in C.B-17 SCID mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol 1996, 148:1503-1515.
14. Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos JC, Bhan AK, Burakoff SJ, Wang B, Terhorst C: Severe colitis in mice with aberrant thymic selection. Immunity 1995, 3:27-38.
15. Spiegel AM, Elson CO, Sartor RB, Tennyson GS, Riddell RH: G protein gene knockout hits the gut. Experimental models of inflammatory bowel disease. Nat Med 1995, 1:522-524.
16. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH: Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 1994, 107:1726-1735.
17. Watanabe M, Ueno Y, Yajima T, Okamoto S, Hayashi T, Yamazaki M, Iwao Y, Ishii H, Habu S, Uehira M, et al.: Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998, 187:389-402. This report demonstrates that chronic mucosal inflammation can also be mediated by dysregulation of colonic epithelial cell-derived IL-7.
18. Mizoguchi A, Mizoguchi E, Chiba C, Spiekermann GM, Tonegawa S, Nagler-Anderson C, Bhan AK: Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J Exp Med 1996, 183:847-856.
19. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK: Role of appendix in the development of inflammatory bowel disease in TCR-α mutant mice. J Exp Med 1996, 184:707-715.
20. Takahashi I, Kiyono H, Hamada S: CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor α chain-deficient mice. Gastroenterology 1997, 112:1876-1886. The first report to demonstrate that a murine model of intestinal inflammation that resembles ulcerative colitis is mediated by an increased Th2 (IL-4) cytokine secretion.
21. Mizoguchi A, Mizoguchi E, Tonegawa S, Bhan AK: Alteration of a polyclonal to an oligoclonal immune response to cecal aerobic bacterial antgens in the TCR alpha mutant mice with inflammatory bowel disease. Int Immunol 1996, 8:1387-1394.
22. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, Elson EO: CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998. 187:855-864. In-depth studies demonstrating that T cells reactive with conventional antigens of the enteric bacterial flora can mediate intestinal inflammation.
23. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB: Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 1996, 98:945-953.
24. Sartor R: Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In Inflammatory Bowel Disease, edn. 4. Edited by Kirsner J, Shorter R. Baltimore: Williams and Wilkins; 1995:96-124.
25. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996, 26:934-938.
26. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W: Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996, 183:2605-2616.
27. Kelsall B, Strober W: Peyer's patch dendritic cells and the induction of mucosal immune responses. Res Immunol 1997, 148:490-497. Updated review on the role of dendritic cells and antigen presentation.
28. Kosiewicz MM, Krishnan A, Shah M, Bentz M, Nast C, Matsumoto S, Cominelli F: Characterization of a new spontaneous murine model of inflammatory bowel disease [abstract]. Gastroenterology 1998, 114:G4142. Discussion of a newer spontaneous model of colitis that most closely resembles Crohn's disease and seems to be mediated by a dysregulated Th1 T-cell response.
29. Bouma G, Crusius JBA, Pool MO, Kolkman JJ, von Blomberg BME, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SGM, Pena AS: Secretion of tumor necrosis factor a and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996, 43:456-463.
30. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, Bell JI, Jewell DP: Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet 1996, 14:199-202.
31. Ohmen JD, Yang HY, Yamamoto KK, Zhao HY, Ma Y, Bentley LG, Huang Z, Gerwehr S, Pressman S, McElree C, et al.: Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease but not in ulcerative colitis. Hum Mol Genet 1996, 5:1679-1683.
32. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of colonic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
33. Chen Y, Kuchroo VK, Inobe J, Hafler D, Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
34. Strober W, Kelsall B, Marth T: Oral tolerance. J Clin Immunol 1998, 18:1-30. Comprehensive review on antigen presentation and presentation of mucosal homeostasis.
35. Weiner HL: Oral tolerance. Proc Natl Acad Sci U S A 1994, 91:10764-10765.
36. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1 -mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996, 183:2669-2674.
37. Snider DP: The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol 1995, 15:317-348.
38. Fuss IJ, Boirivant M, Chu AC, Strober W: Oxazolone-induced colitis: an animal model of ulcerative colitis treatable with antibodies to IL-4 [abstract]. Gastroenterology 1998, 114:G4020.
39. Monteleone G, Biancone L, Marasco R, Marrone G, Marasco O, Luzza F, Pallone F: Interleukin-12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
40. Neurath MF, Fuss I, Schurmann G, Pettersson S, Herfarth C, Muller-Lobeck H, Meyer zum Buschenfelde KH, Strober W: Upregulation of the IL-12/STAT-4 signaling pathway distinguishes Crohn's disease from ulcerative colitis [abstract]. Gastroenterology 1998, 114:64299. These studies show a clear delineation between Crohn's disease and ulcerative colitis with respect to the secretion of IL-12 and the expression of the STAT-4 signaling molecule.
41. Fuss IJ, Neurath MF, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL 5. J Immunol 1996, 157:1261-1270.
42. Parronchi P, Romagni P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagni S: Type 1 T-helper cell predominance and IL-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997, 150:823-832.
43. Mullin GE, Maycon ZR, Braun-Elwert L, Cerchia R, James SP, Katz S, Weissman GS, McKinley MJ, Fisher SE: Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflamm Bowel Dis 1996, 2:16-26.
44. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT: Interleukin-2 and interferon-γ secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993, 78:127-131.
45. Neurath M, Fuss I, Pasparkis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W, Kollias G: Predominant pathogenic role of tumor necrosis factor α in experimental colitis. Eur J Immunol 1997, 27:1743-1750.
46. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337:1029-1035. Controlled study documenting the clinical efficacy of anti-TNF-α in the treatment of Crohn's disease.
47. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C: Interleukin-4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996, 110:1683-1695.
48. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995, 102:448-455.